Cardiff Oncology (CRDF) Appoints Leila Alland as Interim CMO

What happened

Cardiff Oncology appointed Leila Alland, MD, as interim Chief Medical Officer, succeeding Roger Sidhu, MD. The company targets a Phase 3 trial start in the first quarter of 2027 for onvansertib in first-line RAS-mutated mCRC, while a Phase 2 trial remains ongoing.

Confirmed

Global impact / market context

An interim chief medical officer change can alter how a small drug developer designs and runs clinical trials. Investors face uncertainty about continuity just as Cardiff plans a costly late-stage study, where delays or redesigns could raise spending and push back the timeline for possible approval.

Analyst inference

Cardiff is a clinical-stage oncology company with no approved product revenue, so its value rests mainly on trial progress. The Phase 3 start date and Phase 2 data, including median progression-free survival (time without the cancer worsening), that is not yet reached at the 30 mg dose, are the main catalysts investors track.

Analyst inference

What to watch

1. Leila Alland is interim Chief Medical Officer, an interim label that may change; watch whether the role becomes permanent and whether clinical strategy or trial timelines shift. Confirmed
2. The company targets a Phase 3 trial start in the first quarter of 2027. Watch for a firm start date, trial funding, and regulatory alignment, which would turn this plan into a larger catalyst. Proposed
3. Phase 2 data on response and durability will shape Phase 3 design and risk. Watch for a clear Phase 2 update, since median progression-free survival at the 30 mg arm is not yet reached. Analyst inference

Evidence

• globenewswire.com